title: Monoclonal antibodies for the treatment of metastases. Evaluation of strategies using a syngeneic rat model.
abstract: To investigate critical factors influencing the localization and antitumor effects of monoclonal antibodies (MAb) or toxic conjugates, we have adapted a single rat sarcoma, HSN, for preferential growth in the lungs, liver, and lymph nodes (the major sites of metastasis in humans) and have raised a panel of syngeneic rat MAbs to a stably-expressed cell surface antigen. Using this model we have shown that localization in tumors is significantly influenced by their anatomical location and vascularization, and the degree of MAb interaction with host cells. Uptake in small hepatic tumors was excellent, but access to lung tumors was limited by the poor permeability of pulmonary vessels. HSN cells transfected with th human IL-2 gene and coinjected in low numbers with parental tumors secreted sufficient cytokine to enhance the local permeability of vessels and doubled MAb localization in tumors without any systemic toxicity, suggesting that regional delivery of IL-2 may be used to enhance MAb localization in this situation. In order to extent the applicability of the model to studies of MAbs raised against human tumor targets, we have transfected the human c-erb B-2 gene (homolog of the rat neu) into the highly metastatic HSN.LV subline. MAbs raised against the external domain of the p185 product can now be screened for their ability to localize in metastases, and for various conjugates to inhibit tumor growth either independently of, or in association with, a fully functional immune system.
authors.affiliation: Section of Immunology, Institute of Cancer Research, Sutton, UK.
authors.forename: S A
authors.initials: SA
authors.lastname: Eccles
authors.forename: G
authors.initials: G
authors.lastname: Box
authors.forename: W
authors.initials: W
authors.lastname: Court
authors.forename: M K
authors.initials: MK
authors.lastname: Collins
authors.forename: C J
authors.initials: CJ
authors.lastname: Dean
mesh_terms: D000818:Animals; D000911:Antibodies, Monoclonal / Q000032:analysis / Q000493:pharmacokinetics / Q000627:therapeutic use*; D001822:Body Burden; D002199:Capillary Permeability / Q000276:immunology / Q000502:physiology; D006801:Humans; D007376:Interleukin-2 / Q000494:pharmacology; D008113:Liver Neoplasms / Q000276:immunology / Q000473:pathology; D009362:Neoplasm Metastasis / Q000276:immunology*; D009369:Neoplasms / Q000276:immunology / Q000503:physiopathology; D051381:Rats; D012039:Regional Blood Flow; D012513:Sarcoma, Experimental / Q000098:blood supply / Q000276:immunology; D014407:Tumor Cells, Cultured
chemical_list: D000911:Antibodies, Monoclonal; D007376:Interleukin-2